Stocks and Investing Stocks and Investing
Tue, December 6, 2016
Mon, December 5, 2016
Fri, December 2, 2016
Thu, December 1, 2016
Wed, November 30, 2016
Tue, November 29, 2016

Gena Wang Downgraded (BMRN) to Hold and Decreased Target to $105 on, Nov 29th, 2016


Published on 2024-10-25 19:27:40 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Downgraded "BioMarin Pharmaceutical Inc." (BMRN) to Hold and Decreased Target from $125 to $105 on, Nov 29th, 2016.

Gena has made no other calls on BMRN in the last 4 months.



There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold on, Monday, November 7th, 2016


These are the ratings of the 2 analyists that currently disagree with Gena


  • Andrew Peters of "Deutsche Bank" Initiated at Strong Buy on, Thursday, November 3rd, 2016
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Increased Target to $127 on, Friday, August 5th, 2016